Tivantinib

Tivantinib structure

Tivantinib (developmental code names ARQ 197) is an experimental drug that has been studied for the treatment of cancer. It is an orally administered, small molecule that acts as a selective inhibitor of the c-Met receptor tyrosine kinase. The c-Met receptor has been implicated in the growth, invasion, and metastasis of various types of cancers, making it a target for cancer therapy.

Mechanism of Action[edit | edit source]

Tivantinib works by selectively inhibiting the activity of the c-Met receptor tyrosine kinase. This receptor is often overexpressed or mutated in many types of solid tumors, including lung cancer, hepatocellular carcinoma (HCC), and gastric cancer, leading to enhanced cancer cell growth, survival, angiogenesis, and metastasis. By inhibiting this receptor, tivantinib is thought to block these processes, thereby inhibiting tumor growth and spread.

Clinical Trials[edit | edit source]

Tivantinib has been evaluated in various phases of clinical trials for its efficacy and safety in treating different types of cancers. One of the most notable studies was its Phase III trial in patients with hepatocellular carcinoma. However, the results have been mixed, with some trials showing benefit and others not meeting their primary endpoints. For example, in hepatocellular carcinoma, tivantinib has shown promise in patients with MET-high tumors but did not demonstrate a significant improvement in overall survival in a broader patient population.

Adverse Effects[edit | edit source]

The adverse effects associated with tivantinib are similar to those of other targeted cancer therapies and may include nausea, vomiting, fatigue, and hematologic effects such as anemia. The severity of these side effects varies among patients, and managing them is an important aspect of treatment with tivantinib.

Current Status[edit | edit source]

As of the last update, tivantinib has not received approval from regulatory agencies such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe for the treatment of any cancer. Research and development efforts continue, with ongoing studies aimed at identifying specific patient populations that may benefit from tivantinib, particularly those with MET-high tumors.

Conclusion[edit | edit source]

Tivantinib represents a potential new option for the treatment of various cancers, particularly for patients with tumors that exhibit high levels of c-Met expression. While clinical trials have shown some promise, further research is necessary to fully understand its efficacy, safety, and the patient populations that may derive the most benefit from this targeted therapy.